Roche’s Tecentriq (atezolizumab) + Abraxane Receives CHMP’s Recommendation for its Approval in Europe

Shots:

• The CHMP recommendation is based on P-III IMpassion130 study results assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with 902 patients in ratio (1:1) with unresectable LA or m-TNBC with no prior treatment for m-breast cancer
• The P-III Impassion130 results: m-PFS (7.5 vs 5.0 mos.); OS in PD-L1-positive population (25.0 vs 18.0 mos.); OS in IIT population (21.0 vs 18.7 mos.)
• Tecentriq is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptor, thus enabling the interaction of T-cells and is an approved therapy in the US & EU as monothx. or combination therapy for NSCLC, SCLC, m-UC and PD-L1+ triple-negative breast cancer

Click here to read full press release/ article | Ref: Roche | Image: Chicago Tribune